Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma (B-NHL).

2574 Background: CD22 is expressed on most B-NHL. INO, an anti-CD22 antibody linked to calicheamicin, has activity in refractory B-NHL. This study hypothesized that INO plus rituximab, gemcitabine,...